Literature DB >> 9437438

Neuropathologic diagnosis of Alzheimer disease: consensus between practicing neuropathologists?

C Bancher1, W Paulus, K Paukner, K Jellinger.   

Abstract

In an attempt to gather information on procedures, criteria, and possible difficulties, we have sent a detailed questionnaire on the postmortem diagnosis of Alzheimer disease (AD) to 169 neuropathologists in the German-speaking countries--Germany, Austria, and Switzerland. Of a total of 104 responses, 65 completed questionnaires were evaluated statistically. Fifty-nine percent of all respondents consider the neuropathologic diagnosis of AD a problem. Although 38% consider themselves able to establish the diagnosis without knowledge of clinical data, 29% do not believe this is possible. Thirty-eight percent opine that the presence of neurofibrillary tangles is not a prerequisite for a positive diagnosis, and 3% believe that examination of the hippocampal formation is unnecessary. For 6% of the respondents, neither a silver stain a silver stain nor thioflavin S is necessary. Ninety-seven percent believe that the availability of explicit diagnostic criteria would be helpful; by contrast, only 43% have exact knowledge of the National Institute of Aging criteria, and only 29% have exact knowledge of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria. Only every fourth neuropathologist uses these criteria regularly, and the validity of current diagnostic criteria is challenged by a considerable number of respondents. Many pathologists consider the quantification of plaques and tangles problematic, are confused by a lacking correlation of the pathology with the clinical picture, and believe that the gray zone between normal aging and full-fledged AD represents a major diagnostic problem. Our survey shows that there currently is no consensus on diagnostic procedures and criteria used in practice. This stresses the need for precise diagnostic guidelines and continuing information of actively practicing neuropathologists to achieve higher interlaboratory reliability of the diagnosis of AD.

Entities:  

Mesh:

Year:  1997        PMID: 9437438

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  7 in total

1.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

2.  Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity.

Authors:  Peter T Nelson; Gregory A Jicha; Frederick A Schmitt; Huaichen Liu; Daron G Davis; Marta S Mendiondo; Erin L Abner; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2007-12       Impact factor: 3.685

3.  Selective accumulation of aluminum in cerebral arteries in Alzheimer's disease (AD).

Authors:  Surjyadipta Bhattacharjee; Yuhai Zhao; James M Hill; Frank Culicchia; Theodore P A Kruck; Maire E Percy; Aileen I Pogue; J R Walton; Walter J Lukiw
Journal:  J Inorg Biochem       Date:  2013-05-21       Impact factor: 4.155

4.  Primary age-related tauopathy (PART): a common pathology associated with human aging.

Authors:  John F Crary; John Q Trojanowski; Julie A Schneider; Jose F Abisambra; Erin L Abner; Irina Alafuzoff; Steven E Arnold; Johannes Attems; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Marla Gearing; Lea T Grinberg; Patrick R Hof; Bradley T Hyman; Kurt Jellinger; Gregory A Jicha; Gabor G Kovacs; David S Knopman; Julia Kofler; Walter A Kukull; Ian R Mackenzie; Eliezer Masliah; Ann McKee; Thomas J Montine; Melissa E Murray; Janna H Neltner; Ismael Santa-Maria; William W Seeley; Alberto Serrano-Pozo; Michael L Shelanski; Thor Stein; Masaki Takao; Dietmar R Thal; Jonathan B Toledo; Juan C Troncoso; Jean Paul Vonsattel; Charles L White; Thomas Wisniewski; Randall L Woltjer; Masahito Yamada; Peter T Nelson
Journal:  Acta Neuropathol       Date:  2014-10-28       Impact factor: 17.088

5.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

6.  Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts.

Authors:  Lauren Walker; Kirsty E McAleese; Mary Johnson; Ahmad A Khundakar; Daniel Erskine; Alan J Thomas; Ian G McKeith; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2017-03-06       Impact factor: 3.575

7.  Braak neurofibrillary tangle staging prediction from in vivo MRI metrics.

Authors:  Caroline Dallaire-Théroux; Iman Beheshti; Olivier Potvin; Louis Dieumegarde; Stephan Saikali; Simon Duchesne
Journal:  Alzheimers Dement (Amst)       Date:  2019-09-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.